Skip to main content

Clinical Trials Using Cyclophosphamide

Review the clinical trials studying cyclophosphamide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 376-400 of 424

SJCARB7H3_41BBL for the Treatment of Newly Diagnosed Metastatic High-Risk Osteosarcoma after Standard Chemotherapy, 3CAR4OS Trial
Status: Approved
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
CD70.CAR NK Cells for the Treatment of Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
Status: Approved
Location: M D Anderson Cancer Center, Houston, Texas
A New Molecular Biomarker Test for Adapting Neoadjuvant Treatment in Patients with HER2-Positive Early-Stage Breast Cancer, EUREKA Trial
Status: Approved
Location: 9 locations
Intraperitoneal and Intravenous TROP2 CAR/IL-15 TGFBR2 KO NK Cell Therapy with Cetuximab for the Treatment of Microsatellite Stable Colorectal Cancer with Peritoneal Metastases, Chip-CRC Trial
Status: Approved
Location: M D Anderson Cancer Center, Houston, Texas
TCRalpha/beta and CD19+ depleted Hematopoietic Stem Cell Transplant from Closely Matched Unrelated Donors or Haploidentical Related donors for Blood Disorders in Children and Young Adults
Status: Approved
Location: 2 locations
Genetically Engineered Cells (CD45RA-Depleted CD19-CAR T Cells) after Donor Stem Cell Transplantation for the Treatment of Pediatric Patients with Relapsed/Refractory CD19-Positive Blood Cancers, HAPALL Trial
Status: Approved
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
211At-OKT10-B10 and Fludarabine Alone or in Combination with Cyclophosphamide and Low-Dose TBI before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Status: Approved
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Cell Therapy (CIML NK Cells) for the Treatment of Recurrent Myeloid Disease after Donor Blood Stem Cell Transplant
Status: Temporarily Closed to Accrual
Location: 3 locations
CD4-Directed Chimeric Antigen Receptor T-cells for the Treatment of Patients with Relapsed or Refractory CD4+ Hematologic Cancers
Status: Temporarily Closed to Accrual
Location: 3 locations
Testing CC-486 (Oral Azacitidine) plus the Standard Drug Therapy in Patients 75 years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: 148 locations
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients with Chronic Lymphocytic Leukemia
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Tumor Infiltrating Lymphocytes and High-Dose Aldesleukin with or without Autologous Dendritic Cells in Treating Patients with Metastatic Melanoma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients who Undergo a Hematopoietic Stem Cell Transplant
Status: Temporarily Closed to Accrual
Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: 82 locations
Dasatinib and Quercetin with CAR-T Therapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Status: Temporarily Closed to Accrual
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Ponatinib in Combination with Venetoclax and Mini-hyper CVD Chemotherapy for the Treatment of Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Tazemetostat in Combination with CHOP for Previously Untreated Peripheral T-Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: 3 locations
A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
E7777 to Enhance Regulatory T-Cell Depletion Prior to CAR-T for the Treatment of Relapsed/Refractory B-Cell Lymphomas
Status: Temporarily Closed to Accrual
Location: 2 locations
KSQ-001EX for the Treatment of Patients with Advanced or Metastatic Melanoma, Recurrent Non-Small Cell Lung Carcinoma or Advanced Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Targeted CAR-T Cell Therapy (IVS-3001) for the Treatment of Previously Treated Locally Advanced Unresectable or Metastatic HLA-G Positive Solid Tumors
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Atezolizumab in Combination with Cyclophosphamide, Sorafenib, and Bevacizumab for the Treatment of Recurrent or Refractory Solid Tumors in Pediatric Patients, ANGIO-A Study
Status: Temporarily Closed to Accrual
Location: 2 locations
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
Testing the Safety and Feasibility of HER2 CAR T Cells in Patients with Recurrent or Refractory Ependymoma
Status: Temporarily Closed to Accrual
Location: 10 locations
Fludarabine and Cyclophosphamide with or without Rituximab before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California